Polina A. Nikitina

Dr. Polina A. Nikitina

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Chemistry of Heterocyclic Compounds
Verified
Journal Article
Closed access
PDF file
PNPolina A. Nikitina
Polina A. Nikitina
VPValery P. Perevalov
Valery P. Perevalov

1 April 2013 in Tetrahedron
Verified
Journal Article
Closed access
PNPolina A. Nikitina
Polina A. Nikitina
LKLudmila G. Kuz'Mina
Ludmila G. Kuz'Mina
VPValery P. Perevalov
Valery P. Perevalov
ITIosif I. Tkach
Iosif I. Tkach

1 August 2015 in Tetrahedron
Verified
Journal Article
Closed access
PNPolina A. Nikitina
Polina A. Nikitina
APAleksandr S. Peregudov
Aleksandr S. Peregudov
TKTatiana Yu. Koldaeva
Tatiana Yu. Koldaeva
LKLudmila G. Kuz'MIna
Ludmila G. Kuz'MIna
EAEvgeniy I. Adiulin
Evgeniy I. Adiulin
VPValery P. Perevalov
Valery P. Perevalov

1 March 2019 in Russian Chemical Bulletin
Verified
Journal Article
Closed access
PDF file
PNPolina A. Nikitina
Polina A. Nikitina
NBN. I. Bormotov
N. I. Bormotov
LSL. N. Shishkina
L. N. Shishkina
ATA. Ya. Tikhonov
A. Ya. Tikhonov
VPV. P. Perevalov
V. P. Perevalov

19 November 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PNPolina A. Nikitina
Polina A. Nikitina
EBE.I. Basanova
E.I. Basanova
ENE.B. Nikolaenkova
E.B. Nikolaenkova
IOI.A. Os'KIna
I.A. Os'KIna
OSO.A. Serova
O.A. Serova
ATA.YA. Tikhonov
A.YA. Tikhonov

5 July 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EBElizaveta I. Basanova
Elizaveta I. Basanova
EKEkaterina A. Kulikova
Ekaterina A. Kulikova
NBNikolai I. Bormotov
Nikolai I. Bormotov
OSOlga A. Serova
Olga A. Serova
LSLarisa N. Shishkina
Larisa N. Shishkina
PNPolina A. Nikitina
Polina A. Nikitina
Scientific interest in orthopoxvirus infections and search for new highly effective compounds possessing antiviral activity against orthopoxviruses have significantly increased as a result of worldwide mpox outbreak in 2022. The present work deals with the synthesis of new 2-arylimidazoles exhibiting in vitro activity not only against the vaccinia virus, cowpox virus and ectromelia (mousepox) virus but also against the variola virus. Among the imidazole derivatives under consideration (1-hydroxyimidazoles, 1-methoxyimidazoles, 1-benzyloxyimidazoles, and imidazole N-oxides), the most promising antiviral activity is demonstrated by 1-hydroxyimidazoles, which may exist as two prototropic tautomers. Both of these tautomers may be manifested in different crystal structures of these compounds, according to single-crystal X-ray diffraction analysis, while predominantly one of them (N-hydroxy-tautomeric form) is present in DMSO-d6 solutions and in the gaseous state, as shown by NMR spectroscopy and quantum-chemical calculations. The leader compound 1-hydroxy-2-(4-nitrophenyl)imidazole 4a demonstrated the highest selectivity indices against the vaccinia virus (SI = 1072) and the variola virus (SI = 373).